Mitoxantrone Shows In Vitro, but Not In Vivo Antiviral Activity against Human Respiratory Syncytial Virus

Human respiratory syncytial virus (HRSV) is the most common cause of severe respiratory infections in infants and young children, often leading to hospitalization. In addition, this virus poses a serious health risk in immunocompromised individuals and the elderly. HRSV is also a major nosocomial ha...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicines 2021-09, Vol.9 (9), p.1176
Main Authors: de la Sota, Patricia G., Lorente, Elena, Notario, Laura, Mir, Carmen, Zaragoza, Oscar, López, Daniel
Format: Article
Language:English
Subjects:
Animals
Anthraquinone
Antiviral activity
antivirals
Bioluminescence
Drinking water
Drug development
Drug dosages
drugs
Heparan sulfate
Hospitals
HRSV
Infections
Mitoxantrone
Pathogens
Pharmaceutical industry
Protein expression
Proteins
Public health
Respiratory syncytial virus
RNA polymerase
Severe acute respiratory syndrome coronavirus 2
Software
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Human respiratory syncytial virus (HRSV) is the most common cause of severe respiratory infections in infants and young children, often leading to hospitalization. In addition, this virus poses a serious health risk in immunocompromised individuals and the elderly. HRSV is also a major nosocomial hazard in healthcare service units for patients of all ages. Therefore, the development of antiviral treatments against HRSV is a global health priority. In this study, mitoxantrone, a synthetic anthraquinone with previously reported in vitro antiprotozoal and antiviral activities, inhibits HRSV replication in vitro, but not in vivo in a mice model. These results have implications for preclinical studies of some drug candidates.
ISSN:2227-9059
2227-9059
DOI:10.3390/biomedicines9091176